Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
BETHESDA, Md., March 18, 2008 /PRNewswire-FirstCall/ -- Micromet, Inc. , a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, announced that five posters will be presented on April 14, 2008, at the annual meeting of the American Society for Cancer Research (AACR) to be held at the San Diego Convention Center, California. The five posters showcase recent progress on the company's proprietary BiTE(R) antibody platform and present preclinical data for new BiTE antibodies. BiTE antibodies are designed to direct the body's cytotoxic, or cell-destroying, T cells against tumor cells, and represent a new therapeutic approach to cancer therapy.
A first poster reports that BiTE antibody MT110, which has completed preclinical development for the treatment of patients with EpCAM-expressing adenocarcinoma, can be administered to primates with good bioavailability by subcutaneous delivery (abstract no. 2403).
Jointly with its partner Medimmune, a second poster is presented where BiTE antibody MT103 (MEDI-538), which is in phase 1 and 2 clinical studies, is shown to exhibit anti-tumor activity when subcutaneously delivered to mice (abstract no. 2131).
A third poster describes the conversion of the commercial antibodies trastuzumab and cetuximab (Genentech's and Roche's Herceptin(R) and Imclone Systems Incorporated, Bristol-Myers Squibb's and Merck KGaA's Erbitux(R)) into highly active BiTE antibodies.
A fourth poster presents data on the in vivo and in vitro activity of human BiTE antibodies to CD33 and MCSP for the treatment of acute myelogenous leukaemia and melanoma, respectively (abstract no. 2404).
A fifth poster explores the therapeutic index of an anti-EpCAM BiTE antibody in a mouse model (abstract no. 2130)). It is also shown that under continuous treatment of mice with BiTE antibody, T cells do not lose their cytotoxic and prolific potential but cease to release inflammatory cytokines.
The complete abstracts can be viewed on the web site of AACR (www.aacr.org).
"Our presentations at AACR highlight the significant progress Micromet has made in advancing the BiTE antibody platform," comments Patrick A. Baeuerle, Micromet's chief scientific officer. "We present several new BiTE candidates on a novel human BiTE antibody platform, demonstrate that BiTE antibodies can be delivered subcutaneously, and show that cytotoxic T cell activity is not impaired by long-term BiTE treatment and finally, that we can convert marketed therapeutic antibodies into highly active BiTE antibodies."
Schlereth, B. et al. Feasibility of Repeated Subcutaneous Delivery Establishes a New Route of Administration for Treating Cancer Patients with EpCAM-specific BiTE Antibody MT110. Annual Meeting of AACR, San Diego, 2008, Abstract No. 2403 (board #17, April 14, 2008)
Mulgrew K. et al. Bioavailability, pharmacodynamic activity, and anti- tumor efficacy of the CD19/CD3-bispecific BiTE antibody MEDI-538 (MT103) delivered subcutaneously in animal models. Annual Meeting of AACR, San Diego, 2008, Abstract No. 2131 (board #6, April 14, 2008)
Lutterbuese, R. et al. Conversion of Cetuximab and Trastuzumab into T Cell-engaging BiTE Antibodies Creates Novel Drug Candidates with Superior Anti-tumor Activity. Annual Meeting of AACR, San Diego, 2008, Abstract No. 2402 (board #16, April 14, 2008)
Kischel, R. et al. Characterization of Novel CD33- and MCSP-specific BiTE Antibodies for the Treatment of Acute Myeloid Leukaemia and Melanoma, Respectively, that Are Fully Human in Sequence. Annual Meeting of AACR, San Diego, 2008, Abstract No. 2404 (board #18, April 14, 2008)
Amann, M. et al. Long-term Treatment of Mice with an EpCAM (CD326)- specific BiTE Antibody Reveals a Therapeutic Window and Sustained Activity of T Cells. Annual Meeting of AACR, San Diego, 2008, Abstract No. 2130 (board #5, April 14, 2008)
About BiTE Antibodies
BiTE(R) antibodies are designed to direct the body's cytotoxic, or cell- destroying, T cells against tumor cells, and represent a new therapeutic approach to cancer therapy. BiTE antibodies have been shown to induce an immunological synapse between a T cell and a tumor cell in the same manner as observed during physiological T cell attacks. These cytolytic synapses enable the delivery of cytotoxic proteins from T cells into tumor cells, ultimately inducing a self-destruction process in the tumor cell referred to as apoptosis, or programmed cell death. In the presence of BiTE antibodies, T cells have been demonstrated to serially eliminate tumor cells, which explains the activity of BiTE antibodies at very low concentrations and at very low ratios of T cells to target cells. Through the process of killing cancer cells, T cells proliferate, which leads to an increased number of T cells at the site of attack.
Several antibodies in Micromet's product pipeline are BiTE antibodies and have been generated based on Micromet's proprietary BiTE product development platform. The most advanced BiTE antibody is MT103 (MEDI-538), targeting CD19, and has provided proof-of-concept in an ongoing phase 1 clinical study in advanced non-Hodgkin's lymphoma patients. A first BiTE antibody, MT110, targeting EpCAM (CD326) has completed and BiTE antibodies to CEA and MCSP, are in pre-clinical development.
About Micromet, Inc. (www.micromet-inc.com)
Micromet, Inc. is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Three of its antibodies are currently in clinical trials, while the remainder of the product pipeline is in preclinical development. The BiTE(R) antibody MT103 is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia and in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma. BiTE antibodies represent a new class of antibodies that activate a patient's own cytotoxic T cells, considered the most powerful "killer cells" of the human immune system, to eliminate cancer cells. Micromet is developing MT103 in collaboration with MedImmune, Inc., a subsidiary of AstraZeneca plc. The second clinical stage antibody is adecatumumab, also known as MT201, a human monoclonal antibody which targets epithelial cell adhesion molecule (EpCAM)-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. The third clinical stage antibody, MT293 is licensed to TRACON Pharmaceuticals, Inc. and is being developed in a phase 1 clinical trial for the treatment of patients with cancer. In addition, Micromet has established a collaboration with Nycomed for the development and commercialization of MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis.
This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do not demonstrate safety and/or efficacy in subsequent clinical trials, the risk that encouraging results from early research, preclinical studies or clinical trials may not be confirmed upon further analysis of the detailed results of such research, preclinical study or clinical trial, the risk that additional information relating to the safety, efficacy or tolerability of our product candidates may be discovered upon further analysis of preclinical or clinical trial data, the risk that we or our collaborators will not obtain approval to market our product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborators, including MedImmune, Merck Serono, TRACON and Nycomed, for the funding or conduct of further development and commercialization activities relating to our product candidates. You are urged to consider statements that include the words "ongoing," "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "suggests," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. These factors and others are more fully discussed in our periodic reports and other filings with the SEC.
Any forward-looking statements are made pursuant to Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and, as such, speak only as of the date made. Micromet, Inc. undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT: Company, Investor Relations, +1-240-235-0250,, Investors, Susan Noonan, +1-212-966-3650,, Media, Andrea tenBroek, +1-781-684-0770, email@example.com firstname.lastname@example.org email@example.com
Ticker Symbol: (NASDAQ-NMS:MITI)
Terms and conditions of use apply
Copyright © 2008 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
Posted: March 2008